Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 371
Filtrar
2.
JAMA ; 329(18): 1567-1578, 2023 05 09.
Artículo en Inglés | MEDLINE | ID: mdl-37159034

RESUMEN

Importance: There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF). Objective: To assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with IPF. Design, Setting, and Participants: The 2 identically designed, phase 3, randomized clinical trials, ISABELA 1 and ISABELA 2, were conducted in Africa, Asia-Pacific region, Europe, Latin America, the Middle East, and North America (26 countries). A total of 1306 patients with IPF were randomized (525 patients at 106 sites in ISABELA 1 and 781 patients at 121 sites in ISABELA 2). Enrollment began in November 2018 in both trials and follow-up was completed early due to study termination on April 12, 2021, for ISABELA 1 and on March 30, 2021, for ISABELA 2. Interventions: Patients were randomized 1:1:1 to receive 600 mg of oral ziritaxestat, 200 mg of ziritaxestat, or placebo once daily in addition to local standard of care (pirfenidone, nintedanib, or neither) for at least 52 weeks. Main Outcomes and Measures: The primary outcome was the annual rate of decline for forced vital capacity (FVC) at week 52. The key secondary outcomes were disease progression, time to first respiratory-related hospitalization, and change from baseline in St George's Respiratory Questionnaire total score (range, 0 to 100; higher scores indicate poorer health-related quality of life). Results: At the time of study termination, 525 patients were randomized in ISABELA 1 and 781 patients in ISABELA 2 (mean age: 70.0 [SD, 7.2] years in ISABELA 1 and 69.8 [SD, 7.1] years in ISABELA 2; male: 82.4% and 81.2%, respectively). The trials were terminated early after an independent data and safety monitoring committee concluded that the benefit to risk profile of ziritaxestat no longer supported their continuation. Ziritaxestat did not improve the annual rate of FVC decline vs placebo in either study. In ISABELA 1, the least-squares mean annual rate of FVC decline was -124.6 mL (95% CI, -178.0 to -71.2 mL) with 600 mg of ziritaxestat vs -147.3 mL (95% CI, -199.8 to -94.7 mL) with placebo (between-group difference, 22.7 mL [95% CI, -52.3 to 97.6 mL]), and -173.9 mL (95% CI, -225.7 to -122.2 mL) with 200 mg of ziritaxestat (between-group difference vs placebo, -26.7 mL [95% CI, -100.5 to 47.1 mL]). In ISABELA 2, the least-squares mean annual rate of FVC decline was -173.8 mL (95% CI, -209.2 to -138.4 mL) with 600 mg of ziritaxestat vs -176.6 mL (95% CI, -211.4 to -141.8 mL) with placebo (between-group difference, 2.8 mL [95% CI, -46.9 to 52.4 mL]) and -174.9 mL (95% CI, -209.5 to -140.2 mL) with 200 mg of ziritaxestat (between-group difference vs placebo, 1.7 mL [95% CI, -47.4 to 50.8 mL]). There was no benefit with ziritaxestat vs placebo for the key secondary outcomes. In ISABELA 1, all-cause mortality was 8.0% with 600 mg of ziritaxestat, 4.6% with 200 mg of ziritaxestat, and 6.3% with placebo; in ISABELA 2, it was 9.3% with 600 mg of ziritaxestat, 8.5% with 200 mg of ziritaxestat, and 4.7% with placebo. Conclusions and Relevance: Ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF receiving standard of care treatment with pirfenidone or nintedanib or in those not receiving standard of care treatment. Trial Registration: ClinicalTrials.gov Identifiers: NCT03711162 and NCT03733444.


Asunto(s)
Fibrosis Pulmonar Idiopática , Fármacos del Sistema Respiratorio , Anciano , Humanos , Masculino , Fibrosis Pulmonar Idiopática/tratamiento farmacológico , Fibrosis Pulmonar Idiopática/fisiopatología , Pulmón/efectos de los fármacos , Pulmón/fisiopatología , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Resultado del Tratamiento , Ensayos Clínicos Fase III como Asunto , Estudios Multicéntricos como Asunto , Administración Oral , Persona de Mediana Edad , Femenino , Inhibidores de Fosfodiesterasa/farmacología , Inhibidores de Fosfodiesterasa/uso terapéutico , Fármacos del Sistema Respiratorio/farmacología , Fármacos del Sistema Respiratorio/uso terapéutico
3.
Respir Physiol Neurobiol ; 297: 103834, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34954128

RESUMEN

The opioid buprenorphine alters breathing and the cytokine leptin stimulates breathing. Obesity increases the risk for respiratory disorders and can lead to leptin resistance. This study tested the hypothesis that buprenorphine causes dose-dependent changes in breathing that vary as a function of obesity, leptin status, and sex. Breathing measures were acquired from four congenic mouse lines: female and male wild type C57BL/6J (B6) mice, obese db/db and ob/ob mice with leptin dysfunction, and male B6 mice with diet-induced obesity. Mice were injected intraperitoneally with saline (control) and five doses of buprenorphine (0.1, 0.3, 1.0, 3.0, 10 mg/kg). Buprenorphine caused dose-dependent decreases in respiratory frequency while increasing tidal volume, minute ventilation, and respiratory duty cycle. The effects of buprenorphine varied significantly with leptin status and sex. Buprenorphine decreased minute ventilation variability in all mice. The present findings highlight leptin status as an important modulator of respiration and encourage future studies aiming to elucidate the mechanisms through which leptin status alters breathing.


Asunto(s)
Analgésicos Opioides/farmacología , Buprenorfina/farmacología , Leptina/metabolismo , Obesidad/fisiopatología , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Analgésicos Opioides/administración & dosificación , Animales , Buprenorfina/administración & dosificación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Ventilación Pulmonar/efectos de los fármacos , Frecuencia Respiratoria/efectos de los fármacos , Caracteres Sexuales , Volumen de Ventilación Pulmonar
4.
Can J Vet Res ; 85(4): 251-260, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34602729

RESUMEN

Neonatal foals may require prolonged sedation to permit ventilatory support in the first few days of life. The objective of this study was to evaluate and compare the cardiopulmonary effects and clinical recovery characteristics of 2 sedative/analgesia protocols in healthy foals receiving assisted ventilation. Foals were randomized to receive dexmedetomidine, butorphanol, and propofol (DBP) or midazolam, butorphanol, and propofol (MBP) during a 24-hour period. Infusion rates of dexmedetomidine, midazolam, and propofol were adjusted and propofol boluses administered according to set protocols to maintain optimal sedation and muscle relaxation. Ventilatory support variables were adjusted to preset targets. Physiologic variables were recorded, cardiac output (CO) measured (thermodilution), and arterial and mixed venous blood collected for gas analysis at intervals up to 24 hours. Foals in group DBP received dexmedetomidine [2.4 ± 0.5 µg/kg body weight (BW) per hour], butorphanol (13 µg/kg BW per hour), and propofol (6.97 ± 0.86 mg/kg BW per hour), whereas foals in group MBP received midazolam (0.14 ± 0.04 mg/kg BW per hour), butorphanol (13 µg/kg BW per hour), and propofol (5.98 ± 1.33 mg/kg BW per hour). Foals in the DBP group received significantly more propofol boluses (9.0 ± 3.0) than those in the MBP group (4.0 ± 2.0). Although physiologic variables remained within acceptable limits, heart rate (HR), mean arterial pressure (MAP), and cardiac index (CI) were lower in foals in the DBP group than in the MBP group. Times to sternal recumbency, standing, and nursing were significantly shorter in the DBP than MBP group. We found that MBP and DBP protocols are suitable to assist ventilatory support in neonatal foals, although MBP results in a prolonged recovery compared to DBP.


Les poulains nouveau-nés peuvent nécessiter une sédation prolongée pour permettre une assistance ventilatoire au cours des premiers jours de vie. L'objectif de cette étude était d'évaluer et de comparer les effets cardio-pulmonaires et les caractéristiques de récupération clinique de deux protocoles sédatifs/analgésiques chez des poulains sains recevant une ventilation assistée. Les poulains ont été randomisés pour recevoir de la dexmédétomidine, du butorphanol et du propofol (DBP) ou du midazolam, du butorphanol et du propofol (MBP) pendant une période de 24 heures. Les débits de perfusion de dexmédétomidine, de midazolam et de propofol ont été ajustés et des bolus de propofol ont été administrés selon des protocoles définis pour maintenir une sédation et une relaxation musculaire optimales. Les variables d'assistance ventilatoire ont été ajustées à des cibles prédéfinies. Les variables physiologiques ont été enregistrées, le débit cardiaque (CO) mesuré (thermodilution) et le sang artériel et veineux mixte prélevé pour analyse des gaz à des intervalles allant jusqu'à 24 h. Les poulains du groupe DBP ont reçu de la dexmédétomidine [2,4 ± 0,5 µg/kg de poids corporel (PC) par heure], du butorphanol (13 µg/kg de PC par heure) et du propofol (6,97 ± 0,86 mg/kg de PC par heure), tandis que les poulains du groupe MBP ont reçu du midazolam (0,14 ± 0,04 mg/kg de PC par heure), du butorphanol (13 µg/kg de PC par heure) et du propofol (5,98 ± 1,33 mg/kg de PC par heure). Les poulains du groupe DBP ont reçu significativement plus de bolus de propofol (9,0 ± 3,0) que ceux du groupe MBP (4,0 ± 2,0). Bien que les variables physiologiques soient restées dans des limites acceptables, la fréquence cardiaque (FC), la pression artérielle moyenne (MAP) et l'index cardiaque (IC) étaient plus faibles chez les poulains du groupe DBP que dans le groupe MBP. Les temps de décubitus sternal, de station debout et d'allaitement étaient significativement plus courts dans le groupe DBP que dans le groupe MBP. Nous avons constaté que les protocoles MBP et DBP sont adaptés pour assister l'assistance ventilatoire chez les poulains nouveau-nés, bien que le MBP entraîne une récupération prolongée par rapport au DBP.(Traduit par Docteur Serge Messier).


Asunto(s)
Periodo de Recuperación de la Anestesia , Frecuencia Cardíaca/efectos de los fármacos , Caballos/fisiología , Hipnóticos y Sedantes/farmacología , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Animales Recién Nacidos/fisiología , Butorfanol/administración & dosificación , Butorfanol/farmacología , Dexmedetomidina/administración & dosificación , Dexmedetomidina/farmacología , Quimioterapia Combinada , Femenino , Hipnóticos y Sedantes/administración & dosificación , Masculino , Midazolam/administración & dosificación , Midazolam/farmacología , Propofol/administración & dosificación , Propofol/farmacología , Respiración Artificial
5.
Respir Physiol Neurobiol ; 293: 103736, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34224867

RESUMEN

The preBötzinger complex (preBötC) is a medullary area essential for normal breathing and widely recognized as necessary and sufficient to generate the inspiratory phase of respiration. It has been studied mainly in rodents. Here we report the main results of our studies revealing the characteristics of the rabbit preBötC identified by means of neuronal recordings, D,L-homocysteic acid microinjections and histological controls. A crucial role in the respiratory rhythmogenesis within this neural substrate is played by excitatory amino acids, but also GABA and glycine display important contributions. Increases in respiratory frequency are induced by microinjections of neurokinins, somatostatin as well by serotonin (5-HT) through an action on 5-HT1A and 5-HT3 receptors or the disinhibition of a GABAergic circuit. Respiratory depression is observed in response to microinjections of the µ-opioid receptor agonist DAMGO. Our results show similarities and differences with the rodent preBötC and emphasize the importance of comparative studies on the mechanisms underlying respiratory rhythmogenesis in different animal species.


Asunto(s)
Generadores de Patrones Centrales/fisiología , Bulbo Raquídeo/fisiología , Neurotransmisores/farmacología , Centro Respiratorio/fisiología , Fenómenos Fisiológicos Respiratorios , Animales , Generadores de Patrones Centrales/efectos de los fármacos , Bulbo Raquídeo/efectos de los fármacos , Conejos , Centro Respiratorio/efectos de los fármacos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos
6.
Respir Physiol Neurobiol ; 293: 103737, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34229065

RESUMEN

Effects of acetylcholine (ACh) on respiratory activity have been an intriguing theme especially in relation to central chemoreception and the control of hypoglossal nerve activity. We studied the effects of ACh on hypoglossal and phrenic (C4) nerve activities and inspiratory and pre-inspiratory neurons in the rostral ventrolateral medulla in brainstem-spinal cord preparations from newborn rats. ACh application increased respiratory rhythm, decreased inspiratory hypoglossal and C4 nerve burst amplitude, and enhanced pre-inspiratory hypoglossal activity. ACh induced membrane depolarization of pre-inspiratory neurons that might be involved in facilitation of respiratory rhythm by ACh. Effects of ACh on hypoglossal and C4 nerve activity were partially reversed by a nicotinic receptor blocker, mecamylamine. Further application of a muscarinic receptor antagonist, oxybutynin, resulted in slight increase of hypoglossal (but not C4) burst amplitude. Thus, ACh induced different effects on hypoglossal and C4 nerve activity in the brainstem-spinal cord preparation.


Asunto(s)
Acetilcolina/farmacología , Tronco Encefálico/efectos de los fármacos , Nervio Hipogloso/efectos de los fármacos , Nervio Frénico/efectos de los fármacos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Animales , Animales Recién Nacidos , Células Quimiorreceptoras/efectos de los fármacos , Núcleos Talámicos Intralaminares/efectos de los fármacos , Neuronas Motoras/efectos de los fármacos , Ratas , Ratas Wistar
7.
Respir Physiol Neurobiol ; 294: 103743, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34273553

RESUMEN

Neuroplasticity is a fundamental property of the respiratory control system, enabling critical adaptations in breathing to meet the challenges, but little is known whether neonates express neuroplasticity similar to adults. We tested the hypothesis that, similar to adults, tyrosine receptor kinase B (TrkB) or adenosine A2a receptor activation in neonates are independently sufficient to elicit respiratory motor facilitation, and that co-induction of TrkB and A2a receptor-dependent plasticity undermines respiratory motor facilitation. TrkB receptor activation with 7,8-dihydroxyflavone (DHF) in neonatal brainstem-spinal cord preparations induced a long-lasting increase in respiratory motor output in 55 % of preparations, whereas adenosine A2a receptor activation with CGS21680 only sporadically induced respiratory motor plasticity. CGS21680 and DHF co-application prevented DHF-dependent respiratory motor facilitation, whereas co-application of MSX-3 (adenosine A2a receptor antagonist) and DHF more rapidly induced respiratory motor plasticity. Collectively, these data suggest that mechanisms underlying respiratory neuroplasticity may be only partially operational in early neonatal life, and that adenosine A2a receptor activation undermines TrkB-induced respiratory plasticity.


Asunto(s)
Agonistas del Receptor de Adenosina A2/farmacología , Antagonistas del Receptor de Adenosina A2/farmacología , Flavonas/farmacología , Plasticidad Neuronal/fisiología , Receptor de Adenosina A2A/metabolismo , Receptor trkB/agonistas , Receptor trkB/metabolismo , Fenómenos Fisiológicos Respiratorios , Adenosina/análogos & derivados , Adenosina/farmacología , Animales , Animales Recién Nacidos , Tronco Encefálico/efectos de los fármacos , Modelos Animales de Enfermedad , Plasticidad Neuronal/efectos de los fármacos , Fenetilaminas/farmacología , Ratas , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Médula Espinal/efectos de los fármacos
8.
Sci Rep ; 11(1): 11781, 2021 06 03.
Artículo en Inglés | MEDLINE | ID: mdl-34083710

RESUMEN

Tiger milk mushroom (TMM; Lignosus rhinocerus) have been used for a long time by indigenous communities in South East Asia regions as traditional medicine for different ailments, including respiratory disorders. The beneficial effects of TMM have been proven through in vivo and in vitro models, but these effects have yet to be validated in a clinical study. In this study, the beneficial effects of TMM supplementation were investigated in 50 voluntary participants. Participants were required to take 300 mg of TMM twice daily for three months. Level of interleukin 1ß (IL-1ß), interleukin 8 (IL-8), immunoglobulin A (IgA), total antioxidant capacity, malondialdehyde (MDA), 3-nitrotyrosine (3-NT), 8-hydroxydeoxyguanosine (8-OHdG), pulmonary function and respiratory symptoms were assessed during baseline and monthly follow-up visits. Results demonstrated that supplementation of TMM significantly (p < 0.05) suppressed the level of IL-1ß, IL-8, MDA, as well as respiratory symptoms. In additional to that, TMM also significantly (p < 0.05) induced the level of IgA, total antioxidant capacity, as well as pulmonary function. Analyses of data indicated that gender and BMI were factors influencing the outcomes of antioxidant status. Collectively, our findings suggested that TMM supplementation effectively improves respiratory health, immunity and antioxidant status.


Asunto(s)
Agaricales/química , Antioxidantes/farmacología , Suplementos Dietéticos , Factores Inmunológicos/farmacología , Polyporaceae/química , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Adulto , Antioxidantes/química , Biomarcadores , Presión Sanguínea/efectos de los fármacos , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Inmunidad/efectos de los fármacos , Factores Inmunológicos/química , Masculino , Medicina Tradicional , Persona de Mediana Edad
9.
Nutrients ; 13(4)2021 Mar 27.
Artículo en Inglés | MEDLINE | ID: mdl-33801665

RESUMEN

The assessment of ventilatory efficiency is critical to understanding the matching of ventilation (VE) and perfusion in the lungs during exercise. This study aimed to establish a causal physiological relationship between ventilatory efficiency and resistance exercise performance after beetroot juice (BJ) intake. Eleven well-trained males performed a resistance exercise test after drinking 140 mL of BJ (~12.8 mmol NO3-) or a placebo (PL). Ventilatory efficiency was assessed by the VE•VCO2-1 slope, the oxygen uptake efficiency slope and the partial pressure of end-tidal carbon dioxide (PetCO2). The two experimental conditions were controlled using a randomized, double-blind crossover design. The resistance exercise test involved repeating the same routine twice, which consisted of wall ball shots plus a full squat (FS) with a 3 min rest or without a rest between the two exercises. A higher weight lifted was detected in the FS exercise after BJ intake compared with the PL during the first routine (p = 0.004). BJ improved the VE•VCO2-1 slope and the PetCO2 during the FS exercise in the first routine and at rest (p < 0.05). BJ intake improved the VE•VCO2-1 slope and the PetCO2 coinciding with the resistance exercise performance. The ergogenic effect of BJ could be induced under aerobic conditions at rest.


Asunto(s)
Atletas , Beta vulgaris/química , Jugos de Frutas y Vegetales , Entrenamiento de Fuerza , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Adulto , Estudios Cruzados , Método Doble Ciego , Humanos , Ácido Láctico/sangre , Masculino , Consumo de Oxígeno/fisiología , Intercambio Gaseoso Pulmonar/fisiología
10.
J Wildl Dis ; 57(2): 357-367, 2021 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-33822147

RESUMEN

Aerial translocation of captured black rhinoceroses (Diceros bicornis) has been accomplished by suspending them by their feet. We expected this posture would compromise respiratory gas exchange more than would lateral recumbency. Because white rhinoceroses (Ceratotherium simum) immobilized with etorphine alone are hypermetabolic, with a high rate of carbon dioxide production (VCO2), we expected immobilized black rhinoceroses would also have a high VCO2. Twelve (nine male, three female; median age 8 yr old [range: 4-25]; median weight 1,137 kg [range: 804-1,234] body weight) wild black rhinoceroses were immobilized by aerial darting with etorphine and azaperone. The animals were in lateral recumbency or suspended by their feet from a crane for approximately 10 min before data were collected. Each rhinoceros received both treatments sequentially, in random order. Six were in lateral recumbency first and six were suspended first. All animals were substantially hypoxemic and hypercapnic in both postures. When suspended by the feet, mean arterial oxygen pressure (PaO2) was 42 mm Hg, 4 mm Hg greater than in lateral recumbency (P=0.030), and arterial carbon dioxide pressure (PaCO2) was 52 mm Hg, 3 mm Hg less than in lateral recumbency (P=0.016). Tidal volume and minute ventilation were similar between postures. The mean VCO2 was 2 mL/kg/min in both postures and was similar to, or marginally greater than, VCO2 predicted allometrically. Suspension by the feet for 10 min did not impair pulmonary function more than did lateral recumbency and apparently augmented gas exchange to a small degree relative to lateral recumbency. The biological importance in these animals of numerically small increments in PaO2 and decrements in PaCO2 with suspension by the feet is unknown. Black rhinoceroses immobilized with etorphine and azaperone were not as hypermetabolic as were white rhinoceroses immobilized with etorphine.


Asunto(s)
Metabolismo Energético/efectos de los fármacos , Etorfina/farmacología , Inmovilización/veterinaria , Perisodáctilos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Animales Salvajes , Diprenorfina/administración & dosificación , Diprenorfina/farmacología , Etorfina/administración & dosificación , Femenino , Hipnóticos y Sedantes/administración & dosificación , Hipnóticos y Sedantes/farmacología , Masculino , Naltrexona/administración & dosificación , Naltrexona/farmacología , Antagonistas de Narcóticos/administración & dosificación , Antagonistas de Narcóticos/farmacología , Postura
11.
Am J Physiol Lung Cell Mol Physiol ; 320(6): L1038-L1056, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-33822645

RESUMEN

Airway oscillometry has become the de facto standard for quality assessment of lung physiology in laboratory animals and has demonstrated its usefulness in understanding diseases of small airways. Nowadays, it is seeing extensive use in daily clinical practice and research; however, a question that remains unanswered is how well physiological findings in animals and humans correlate? Methodological and device differences are obvious between animal and human studies. However, all devices deliver an oscillated airflow test signal and output respiratory impedance. In addition, despite analysis differences, there are ways to interpret animal and human oscillometry data to allow suitable comparisons. The potential with oscillometry is its ability to reveal universal features of the respiratory system across species, making translational extrapolation likely to be predictive. This means that oscillometry can thus help determine if an animal model displays the same physiological characteristics as the human disease. Perhaps more importantly, it can also be useful to determine whether an intervention is effective as well as to understand if it affects the desired region of the respiratory system, e.g., the periphery of the lung. Finally, findings in humans can also inform preclinical scientists and give indications as to what type of physiological changes should be observed in animal models to make them relevant as models of human disease. The present article will attempt to demonstrate the potential of oscillometry in respiratory research, an area where the development of novel therapies is plagued with a failure rate higher than in other disease areas.


Asunto(s)
Asma/tratamiento farmacológico , Asma/fisiopatología , Impedancia Eléctrica/uso terapéutico , Pulmón/fisiopatología , Oscilometría , Animales , Humanos , Pulmón/efectos de los fármacos , Pulmón/fisiología , Oscilometría/métodos , Pruebas de Función Respiratoria/métodos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos
12.
Environ Health Perspect ; 129(1): 17001, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33439053

RESUMEN

BACKGROUND: Climate change models predict that atmospheric carbon dioxide [CO2] levels will be between 700 and 900 ppm within the next 80 y. Despite this, the direct physiological effects of exposure to slightly elevated atmospheric CO2 (as compared with ∼410 ppm experienced today), especially when exposures extend from preconception to adulthood, have not been thoroughly studied. OBJECTIVES: In this study we aimed to assess the respiratory structure and function effects of long-term exposure to 890 ppm CO2 from preconception to adulthood using a mouse model. METHODS: We exposed mice to CO2 (∼890 ppm) from prepregnancy, through the in utero and early life periods, until 3 months of age, at which point we assessed respiratory function using the forced oscillation technique, and lung structure. RESULTS: CO2 exposure resulted in a range of respiratory impairments, particularly in female mice, including higher tissue elastance, longer chord length, and lower lung compliance. Importantly, we also assessed the lung function of the dams that gave birth to our experimental subjects. Even though these mice had been exposed to the same level of increased CO2 for a similar amount of time (∼8wk), we measured no impairments in lung function. This suggests that the early life period, when lungs are undergoing rapid growth and development, is particularly sensitive to CO2. DISCUSSION: To the best of our knowledge, this study, for the first time, shows that long-term exposure to environmentally relevant levels of CO2 can impact respiratory function in the mouse. https://doi.org/10.1289/EHP7305.


Asunto(s)
Dióxido de Carbono , Cambio Climático , Pulmón , Dióxido de Carbono/toxicidad , Femenino , Humanos , Pulmón/anatomía & histología , Pulmón/efectos de los fármacos , Pulmón/fisiología , Embarazo , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos
13.
J Zoo Wildl Med ; 51(4): 994-998, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33480580

RESUMEN

Ketamine-free, midazolam-based protocols have successfully immobilized cervids in the past but their impact on physiological function has not yet been thoroughly investigated. Six deer received IM dexmedetomidine (30.96 ± 3.06 µg/kg) and midazolam (0.31 ± 0.03 mg/kg). Heart rates (HR), respiratory rates (f ), rectal temperature, mean arterial blood pressure (MAP), and oxygen saturation (SpO2) were recorded 25 min after drug delivery (T25) and every 5 min until T55. An arterial blood sample was collected at T40. Mean HR and temperature significantly decreased throughout sedation, but were maintained above critical values (> 60 beats/ min and 37°C, respectively). Although not statistically different, f clinically decreased during sedation. MAP remained within acceptable ranges (60-80 mmHg) and SpO2 above 95%. Mean PaO2 was normal (>80 mmHg), but a mild hypoxemia was observed on two occasions. Recovery was smooth yet prolonged, as the first head movement, attempt to stand, sternal recumbency, and standing position were recorded within 9.36 ± 3.47, 10.32 ± 1.37, 13.13 ± 2.70, and 15.34 ± 2.57 min after IM atipamezole, respectively. This protocol was effective for short-term procedures in captive brown brocket deer, and appeared to be safe on the basis of arterial blood gases and cardiorespiratory variables.


Asunto(s)
Ciervos , Dexmedetomidina/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Imidazoles/farmacología , Midazolam/farmacología , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Antagonistas de Receptores Adrenérgicos alfa 2/administración & dosificación , Antagonistas de Receptores Adrenérgicos alfa 2/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Dióxido de Carbono/sangre , Dexmedetomidina/administración & dosificación , Electrólitos/sangre , Hipnóticos y Sedantes/administración & dosificación , Hipnóticos y Sedantes/farmacología , Imidazoles/administración & dosificación , Midazolam/administración & dosificación , Oxígeno/sangre
14.
Pflugers Arch ; 473(1): 107-120, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33074398

RESUMEN

Oxaliplatin is a platinum-based alkylating chemotherapeutic agent used for cancer treatment. Neurotoxicity is one of its major adverse effects that often demands dose limitation. However, the effects of chronic oxaliplatin on the toxicity of the autonomic nervous system regulating cardiorespiratory function and adaptive reflexes are unknown. Male Sprague Dawley rats were treated with intraperitoneal oxaliplatin (3 mg kg-1 per dose) 3 times a week for 14 days. The effects of chronic oxaliplatin treatment on baseline mean arterial pressure (MAP); heart rate (HR); splanchnic sympathetic nerve activity (sSNA); phrenic nerve activity (PNA) and its amplitude (PNamp) and frequency (PNf); and sympathetic reflexes were investigated in anaesthetised, vagotomised and artificially ventilated rats. The same parameters were evaluated after acute oxaliplatin injection, and in the chronic treatment group following a single dose of oxaliplatin. The amount of platinum in the brain was determined with atomic absorption spectrophotometry. Chronic oxaliplatin treatment significantly increased MAP, sSNA and PNf and decreased HR and PNamp, while acute oxaliplatin had no effects. Platinum was accumulated in the brain after chronic oxaliplatin treatment. In the chronic oxaliplatin treatment group, further administration of a single dose of oxaliplatin increased MAP and sSNA. The baroreceptor sensitivity and somatosympathetic reflex were attenuated at rest while the sympathoexcitatory response to hypercapnia was increased in the chronic treatment group. This is the first study to reveal oxaliplatin-induced alterations in the central regulation of cardiovascular and respiratory functions as well as reflexes that may lead to hypertension and breathing disorders which may be mediated via accumulated platinum in the brain.


Asunto(s)
Fenómenos Fisiológicos Cardiovasculares/efectos de los fármacos , Oxaliplatino/efectos adversos , Oxaliplatino/farmacocinética , Platino (Metal)/metabolismo , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Antineoplásicos/farmacocinética , Barorreflejo/efectos de los fármacos , Sangre/efectos de los fármacos , Células Quimiorreceptoras/efectos de los fármacos , Esquema de Medicación , Frecuencia Cardíaca , Masculino , Oxaliplatino/administración & dosificación , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Nervios Esplácnicos/efectos de los fármacos , Sistema Nervioso Simpático/efectos de los fármacos , Distribución Tisular
15.
Artículo en Inglés | MEDLINE | ID: mdl-33059022

RESUMEN

The effects of high external ammonia (HEA) exposure on breathing and the potential involvement of ammonia transporting Rh proteins in ammonia sensing were assessed in larval and adult zebrafish. Acute exposure of adults to either 250 or 500 µM (NH4)2SO4 caused increases in ventilation amplitude (AVENT) without affecting frequency (fVENT), resembling the ventilatory response to hypercapnia rather than hypoxia, during which fVENT was increased exclusively. The hyperventilatory response to HEA was prevented by hyperoxia, indicating that control of breathing through ammonia sensing is likely secondary to O2 chemoreception. Neuroepithelial cells (NECs) isolated from gill filaments exhibited a significant increase of intracellular [Ca2+] in response to 1 mM NH4Cl but this response was small (roughly 30%) compared to the response to hypercapnia (37.5 mmHg; ~800% increase). Immunohistochemistry (IHC) failed to reveal the presence of Rh proteins (Rhcgb, Rhbg or Rhag) in gill filament NECs. Knockout of rhcgb did not affect the ventilatory response of adults to HEA. Larvae at 4 days post fertilization (dpf) responded to HEA with increases in fVENT (AVENT was not measured). The hyperventilatory response of larvae to HEA was attenuated (60% reduction) after treatment from 0 to 4 dpf with the sympathetic neurotoxin 6-hydroxydopamine. In larvae, Rhcgb, Rhbg and Rhag were undetectable by IHC in cutaneous NECs yet the fVENT to HEA following Rhbg knockdown was slightly (22%) attenuated. Thus, the hyperventilatory response to external ammonia in adult zebrafish, while apparently initiated by activation of NECs, does not require Rhcgb, nor is the entry of ammonia into NECs reliant on other Rh proteins. The lack of colocalization of Rh proteins with NECs suggests that the entry of ammonia into NECs in larvae, also is not facilitated by this family of ammonia channels.


Asunto(s)
Amoníaco/farmacología , Hiperventilación/fisiopatología , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Pez Cebra/fisiología , Amoníaco/metabolismo , Animales , Proteínas Sanguíneas/metabolismo , Calcio/metabolismo , Proteínas de Transporte de Catión/metabolismo , Branquias/citología , Branquias/efectos de los fármacos , Branquias/metabolismo , Inmunohistoquímica , Larva/citología , Larva/efectos de los fármacos , Larva/metabolismo , Glicoproteínas de Membrana/metabolismo , Células Neuroepiteliales/efectos de los fármacos , Células Neuroepiteliales/metabolismo , Pez Cebra/genética , Pez Cebra/metabolismo , Proteínas de Pez Cebra/metabolismo
16.
Am J Physiol Regul Integr Comp Physiol ; 320(2): R116-R128, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33146556

RESUMEN

The evidence is mounting for a role for abnormal signaling of the stress peptide pituitary adenylate cyclase activating polypeptide (PACAP) and its canonical receptor PAC1 in the pathogenesis of sudden infant death syndrome. In this study, we investigated whether the PACAP receptors PAC1 or VPAC2 are involved in the neonatal cardiorespiratory response to hypercapnic stress. We used head-out plethysmography and surface ECG electrodes to assess cardiorespiratory responses to an 8% hypercapnic challenge in unanesthetized and spontaneously breathing 4-day-old PAC1 or VPAC2 knockout (KO) and wild-type mouse pups. We demonstrate that compared with WTs, breathing frequency (RR) and minute ventilation ([Formula: see text]) in PAC1 KO pups were significantly blunted in response to hypercapnia. Although heart rate was unaltered in PAC1 KO pups during hypercapnia, heart rate recovery posthypercapnia was impaired. In contrast, cardiorespiratory impairments in VPAC2 KO pups were limited to only an overall higher tidal volume (VT), independent of treatment. These findings suggest that PACAP signaling through the PAC1 receptor plays a more important role than signaling through the VPAC2 receptor in neonatal respiratory responses to hypercapnia. Thus deficits in PACAP signaling primarily via PAC1 may contribute to the inability of infants to mount an appropriate protective response to homeostatic stressors in childhood disorders such as SIDS.


Asunto(s)
Dióxido de Carbono/toxicidad , Frecuencia Cardíaca/efectos de los fármacos , Hipercapnia/inducido químicamente , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/metabolismo , Receptores de Tipo II del Péptido Intestinal Vasoactivo/metabolismo , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Animales Recién Nacidos , Apnea , Peso Corporal , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Genotipo , Hipercapnia/metabolismo , Masculino , Ratones , Ratones Noqueados , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/metabolismo , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/genética , Receptores de Tipo II del Péptido Intestinal Vasoactivo/genética , Temperatura
17.
Vet Anaesth Analg ; 47(5): 667-671, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32792270

RESUMEN

OBJECTIVE: To investigate the effects of sedative doses of intravenous (IV) medetomidine (MED) or dexmedetomidine (DEX) on selected respiratory variables in dogs. STUDY DESIGN: Randomized, blinded, crossover study. ANIMALS: A total of eight healthy adult research Beagles. METHODS: Dogs breathing room air had an electrical impedance tomography belt placed around the chest and were maintained in right lateral recumbency. Respiratory rate (fR) in movements minute-1 (mpm) and changes in thoracic impedance (ΔZ) in arbitrary units (AU) were recorded for 120 seconds before (T0) and exactly 10 minutes (T10) after the administration of IV DEX (10 µg kg-1) or MED (20 µg kg-1), with a minimum washout period of 10 days between treatments. Minute ΔZ (ΔZ˙) was calculated by multiplying median ΔZ with fR. Data are presented as median (interquartile range). Significance for an overall effect of drugs (DEX versus MED) or treatment (T0 versus T10) was quantified with a two-way analysis of variance for repeated measures, followed by, when appropriate, Wilcoxon's signed rank test for each factor. RESULTS: Overall, fR decreased from 26 (22-29) mpm at T0 to 13 (10-21) mpm at T10 (p = 0.003) and ΔZ increased from 1.133 (0.856-1.599) AU at T0 to 1.650 (1.273-2.813) AU at T10 (p = 0.007), but ΔZ˙ did not change [30.375 (23.411-32.445) AU minute-1 at T0 and 30.581 (22.487-35.091) AU minute-1 at T10]. There was no difference between DEX and MED. Most dogs developed a peculiar breathing pattern characterized by clusters of breaths followed by short periods of apnoea. CONCLUSIONS AND CLINICAL RELEVANCE: Both drugs caused a change in breathing pattern, reduction in fR and increase in ΔZ but did not affect ΔZ˙. It is likely that (dex)medetomidine resulted in reduction in fR and increase in tidal volume without impacting minute volume.


Asunto(s)
Dexmedetomidina/farmacología , Perros , Hipnóticos y Sedantes/farmacología , Medetomidina/farmacología , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Estudios Cruzados , Femenino , Masculino
18.
J Neurophysiol ; 124(3): 740-749, 2020 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-32727273

RESUMEN

All inhalation anesthetics used clinically including isoflurane can suppress breathing; since this unwanted side effect can persist during the postoperative period and complicate patient recovery, there is a need to better understand how isoflurane affects cellular and molecular elements of respiratory control. Considering that astrocytes in a brainstem region known as the retrotrapezoid nucleus (RTN) contribute to the regulation of breathing in response to changes in CO2/H+ (i.e., function as respiratory chemoreceptors), and astrocytes in other brain regions are highly sensitive to isoflurane, we wanted to determine whether and how RTN astrocytes respond to isoflurane. We found that RTN astrocytes in slices from neonatal rat pups (7-12 days postnatal) respond to clinically relevant levels of isoflurane by inhibition of a CO2/H+-sensitive Kir4.1/5.1-like conductance [50% effective concentration (EC50) = 0.8 mM or ~1.7%]. We went on to confirm that similar levels of isoflurane (EC50 = 0.53 mM or 1.1%) inhibit recombinant Kir4.1/5.1 channels but not homomeric Kir4.1 channels expressed in HEK293 cells. We also found that exposure to CO2/H+ occluded subsequent effects of isoflurane on both native and recombinant Kir4.1/5.1 currents. These results identify Kir4.1/5.1 channels in astrocytes as novel targets of isoflurane. These results suggest astrocyte Kir4.1/5.1 channels contribute to certain aspects of general anesthesia including altered respiratory control.NEW & NOTEWORTHY An unwanted side effect of isoflurane anesthesia is suppression of breathing. Despite this clinical significance, effects of isoflurane on cellular and molecular elements of respiratory control are not well understood. Here, we show that isoflurane inhibits heteromeric Kir4.1/5.1 channels in a mammalian expression system and a Kir4.1/5.1-like conductance in astrocytes in a brainstem respiratory center. These results identify astrocyte Kir4.1/5.1 channels as novel targets of isoflurane and potential substrates for altered respiratory control during isoflurane anesthesia.


Asunto(s)
Anestésicos por Inhalación/farmacología , Astrocitos/efectos de los fármacos , Tronco Encefálico/efectos de los fármacos , Células Quimiorreceptoras/efectos de los fármacos , Isoflurano/farmacología , Canales de Potasio de Rectificación Interna/efectos de los fármacos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Animales Recién Nacidos , Modelos Animales de Enfermedad , Células HEK293 , Humanos , Ratas , Proteínas Recombinantes
19.
Theriogenology ; 153: 19-26, 2020 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-32417607

RESUMEN

Among prematurity complications, the most important disorder is structural immaturity and inadequate production of pulmonary surfactant. Betamethasone is the drug of choice to artificially improve pulmonary capacity, thus we aimed to verify the effect of prenatal maternal treatment on lung development of premature puppies. Pregnant bitches were allocated in Term Group (n = 7), Preterm-Treated Group (interrupted pregnancies with maternal administration of betamethasone; n = 7), Preterm-Control Group (untreated interrupted pregnancies; n = 7), Extremely-Preterm Group (interrupted pregnancies at 55d; n = 6). Puppies were subjected to chest radiographic at birth, morphometric description of pulmonary structures and immunohistochemical analysis of surfactant protein B, proliferating cell nuclear antigen and cytokeratin were performed. In Preterm-Treated Group it was possible to more clearly identify cardiac silhouette and lung parenchyma by X-Ray. Saccular formation was higher in Preterm Groups, while Term Group had higher subsaccular development. Lung septation was higher in Treated and Term Groups. Term Group had higher number of cells marked for SP-B, whereas higher proliferation was observed in Extreme-Preterm and Preterm-Control Groups. Preterm Treated and Term Groups had higher tissue differentiation. In conclusion, antenatal maternal corticotherapy in dogs acted by increasing lung morphology and development of areas of gas exchange, regulate metabolism of pulmonary fluids rather than stimulate surfactant production.


Asunto(s)
Betametasona/uso terapéutico , Enfermedades Pulmonares/veterinaria , Pulmón/efectos de los fármacos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Animales , Animales Recién Nacidos , Perros , Femenino , Inmunohistoquímica , Pulmón/patología , Enfermedades Pulmonares/prevención & control , Embarazo , Nacimiento Prematuro , Radiografía Torácica/veterinaria
20.
Rev Mal Respir ; 37(5): 389-398, 2020 May.
Artículo en Francés | MEDLINE | ID: mdl-32278507

RESUMEN

Few studies have examined the effects of air pollution in diffuse interstitial lung disease and they have focused on small numbers of patients. Most data are available in idiopathic pulmonary fibrosis and studies suggest that the level of exposure to pollutants may influence the development of acute exacerbations (ozone and NO2), their incidence (NO2), decline in respiratory function (PM10) and death (PM10 and PM2.5). Several studies show an increase in the incidence of rheumatoid arthritis in people living near busy roads. In systemic scleroderma, hypersensitivity pneumonitis and sarcoidosis although negative effects of pollution have been reported the data are insufficient to be conclusive. Nevertheless, the observed effects of air pollution are consistent with those described for other chronic respiratory diseases. Exposure to pollution induces oxidative stress, chronic inflammation and shortening of telomeres, which are all mechanisms described in fibrogenesis. New epidemiological studies are needed with individual measurements of exposure to outdoor and indoor pollution, as well as fundamental studies to clarify the effect of pollution on fibrogenesis.


Asunto(s)
Contaminación del Aire/efectos adversos , Enfermedades Pulmonares Intersticiales/etiología , Contaminantes Atmosféricos/efectos adversos , Contaminantes Atmosféricos/toxicidad , Contaminación del Aire/estadística & datos numéricos , Alveolitis Alérgica Extrínseca/epidemiología , Alveolitis Alérgica Extrínseca/etiología , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Exposición a Riesgos Ambientales/efectos adversos , Humanos , Fibrosis Pulmonar Idiopática/epidemiología , Fibrosis Pulmonar Idiopática/etiología , Incidencia , Enfermedades Pulmonares Intersticiales/epidemiología , Enfermedades Pulmonares Intersticiales/fisiopatología , Ozono/efectos adversos , Material Particulado/efectos adversos , Fenómenos Fisiológicos Respiratorios/efectos de los fármacos , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...